-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MV-130 in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MV-130 in Urinary Tract Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MV-130 in Urinary Tract Infections Drug Details: MV-130 (Bactek) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Kidney Cancer (Renal Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Kidney Cancer (Renal Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dresbuxelimab in Kidney Cancer (Renal Cell Cancer) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dresbuxelimab in Non-Small Cell Lung Cancer Drug Details: Dresbuxelimab (AK-119)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Antibody-Mediated Rejection (AMR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Antibody-Mediated Rejection (AMR) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Antibody-Mediated Rejection (AMR) Drug Details: Efgartigimod...
-
Sector Analysis
mRNA Vaccines in Infectious Diseases Market Outlook and Trends by Opportunities, Challenges, Unmet Needs, and Competitive Landscape
mRNA Vaccines in Infectious Diseases Market Report Overview The first mRNA vaccines for COVID-19 gained authorization for use in December 2020. These vaccines have been proven highly successful clinically and commercially, dominating the COVID-19 vaccine market. Furthermore, the success of the COVID-19 mRNA vaccines has renewed interest in mRNA vaccines for a variety of other infectious diseases such as influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), Mpox, herpes, Zika virus, and Lyme disease. The report provides an assessment of the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nogapendekin Alfa in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nogapendekin Alfa in Metastatic Colorectal Cancer Drug Details: Nogapendekin...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Analysis and Forecast to 2032
Non-Small Cell Lung Cancer (NSCLC) Report Overview In the 8MM, there were 1,097,467 diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) in 2022. The diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) will register an AGR of more than 2% during 2022-2032. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, NSCLC can begin anywhere in the lungs when the healthy cells that make up the lining of the lungs change and grow out...
-
Analyst Opinions
Online Travel Market Trends and Analysis by Advertising Activity, Challenges, Opportunities and Case Studies, 2023 Update
Online Travel Market Trends Analysis Report Overview The online travel market size in 2022 was estimated at $660.95 billion. The growth is attributed to the effective COVID-19 vaccination programs that contributed to the easing of travel restrictions. Moreover, COVID-19 accelerated the need for travel and tourism companies to adopt a digital strategy as the global pandemic highlighted the need to reduce physical contact, and consumers are still more likely than before to carry out transactions online. Travelers’ requirements are constantly...
-
Track & Monitor
Covid-19 in pharma: synthetic COVID vaccines
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s synthetic COVID vaccines segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Sector Analysis
Syringes, Needles, and Urinary Catheters Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Syringes, Needles, and Urinary Catheters Market Report Overview The syringes, needles, and urinary catheters market size was $25.28 billion in 2023. The market is expected to grow at a CAGR of more than 2% during 2023-2033. The market for syringes, needles, and urinary catheters is profoundly intertwined with healthcare delivery and patient management. These medical devices serve various purposes, from administering medications and vaccines to facilitating urine drainage in individuals with specific medical conditions. Syringes, Needles, and Urinary Catheters Market...